Back to results
US 2004/0001853 A1Published application
Chimeric antigens for eliciting an immune response
AssigneePaladin Labs Inc.
InventorsRajan George, Lorne Tyrrell, Antoine Noujaim
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneePaladin Labs Inc.
InventorsRajan George, Lorne Tyrrell, Antoine Noujaim
Estimating the term…
Disclosed herein are the nucleotide sequences, deduced amino acid sequences as well as methods and compositions necessary to elicit immune responses against chronic Hepatitis B infections in animals and humans. Immune response is enhanced by fusing relevant viral antigens with xenotypic immunoglobulin heavy chain region through a peptide linker and producing the fusion proteins in Baculovirus expression system to incorporate high mannose glycosylation. By virtue of the antibody component, the fusion proteins bind to Fc receptors on the surface of antigen presenting cells, are taken up, processed and derived peptides are presented on MHC Class I, which elicit a CTL (Th1) response. In a similar fashion, due to cross priming and presentation on MHC Class II, will elicit a humoral (Th2) response. In addition, disclosed are the methods of cloning, expression and production of the fusion proteins.
A composition for eliciting a T-cell response in vivo comprising contacting an antigen presenting cell with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment.
A composition for eliciting a T-cell response in vivo comprising contacting an antigen presenting cell with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the immune response domain comprises one or more sequences comprising an HBV core protein, HBV S protein, HBV S1 protein, HBV S2 protein, combinations thereof, and recombinant molecules thereof, and wherein the target binding domain comprises a xenotypic antibody fragment.
A composition for eliciting a T-cell response in vivo comprising contacting an antigen presenting cell with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the immune response domain comprises one or more sequences comprising an DHBV core protein, DHBV Pre-S protein, DHBV PreS/S protein, combinations thereof, and recombinant molecules thereof, and wherein the target binding domain comprises a xenotypic antibody fragment.
A composition for eliciting a T-cell response in vivo comprising contacting an antigen presenting cell with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the immune response domain comprises one or more sequences comprising an HCV Core (1-191) protein, HCV Core (1-177) protein HCV E1 protein, HCV E2 protein, HCV E1-E2 protein, HCV NS5A protein, combinations thereof, and recombinant molecules thereof, and wherein the target binding domain comprises a xenotypic antibody fragment.
A method of enhancing antigen presentation in antigen presenting cells comprising administering a composition comprising a chimeric antigen having an immune response domain and a target binding domain.
A method of activating antigen presenting cells comprising administering a composition comprising a chimeric antigen having an immune response domain and a target binding domain.
A method of eliciting a T cell response comprising administering a composition comprising a chimeric antigen having an immune response domain and a target binding domain.
A method for producing a chimeric antigen in an insect cell expression system.
Dependencies are inferred from the claim text.